Affinity Asset Advisors LLC Makes New Investment in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Affinity Asset Advisors LLC acquired a new position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 1,000,000 shares of the company's stock, valued at approximately $1,580,000. Affinity Asset Advisors LLC owned about 2.86% of RAPT Therapeutics at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in RAPT. Medicxi Ventures Management Jersey Ltd bought a new position in RAPT Therapeutics in the 4th quarter worth about $35,316,000. ADAR1 Capital Management LLC increased its holdings in shares of RAPT Therapeutics by 15,557.5% during the fourth quarter. ADAR1 Capital Management LLC now owns 1,174,313 shares of the company's stock valued at $1,855,000 after purchasing an additional 1,166,813 shares during the period. Geode Capital Management LLC raised its stake in shares of RAPT Therapeutics by 4.9% during the fourth quarter. Geode Capital Management LLC now owns 716,937 shares of the company's stock valued at $1,133,000 after purchasing an additional 33,758 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in RAPT Therapeutics by 25.5% in the fourth quarter. Renaissance Technologies LLC now owns 369,736 shares of the company's stock worth $584,000 after purchasing an additional 75,136 shares during the period. Finally, Los Angeles Capital Management LLC increased its stake in RAPT Therapeutics by 9.2% during the 4th quarter. Los Angeles Capital Management LLC now owns 219,997 shares of the company's stock valued at $348,000 after buying an additional 18,558 shares during the period. 99.09% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of RAPT Therapeutics in a report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $4.00.

RAPT Therapeutics Price Performance

RAPT Therapeutics stock traded down $0.01 during midday trading on Friday, reaching $0.79. The stock had a trading volume of 781,946 shares, compared to its average volume of 1,275,279. The firm's fifty day simple moving average is $1.12 and its two-hundred day simple moving average is $1.35. RAPT Therapeutics, Inc. has a twelve month low of $0.75 and a twelve month high of $8.58. The firm has a market cap of $104.35 million, a price-to-earnings ratio of -0.29 and a beta of -0.29.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last released its earnings results on Thursday, March 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.69). As a group, sell-side analysts predict that RAPT Therapeutics, Inc. will post -2.14 EPS for the current fiscal year.

RAPT Therapeutics Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.